

DT03 Rec'd PCT/PTO 28 FEB 2005

PCT #5

First Class Mail

PTO/SB/21 (09-04)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

**TRANSMITTAL
FORM**

(to be used for all correspondence after initial filing)

Total Number of Pages in This Submission

Application Number

10/510,585

Filing Date

8 October 2004

First Named Inventor

Debra FLEENOR et al.

Art Unit

Examiner Name

Attorney Docket Number

2354 US F

ENCLOSURES (Check all that apply)☐

Fee Transmittal Form

☐

Fee Attached

☐

Amendment/Reply

☐

After Final

☐

Affidavits/declaration(s)

☐

Extension of Time Request

☐

Express Abandonment Request

☒

Information Disclosure Statement

☐

Certified Copy of Priority Document(s)

☐Reply to Missing Parts/
Incomplete Application☐Reply to Missing Parts
under 37 CFR 1.52 or 1.53☐

Drawing(s)

☐

Licensing-related Papers

☐

Petition

☐Petition to Convert to a
Provisional Application☐

Power of Attorney, Revocation

☐

Change of Correspondence Address

☐

Terminal Disclaimer

☐

Request for Refund

☐

CD, Number of CD(s) _____

☐ Landscape Table on CD

Remarks

☐

After Allowance Communication to TC

☐Appeal Communication to Board
of Appeals and Interferences☐Appeal Communication to TC
(Appeal Notice, Brief, Reply Brief)☐

Proprietary Information

☐

Status Letter

☒Other Enclosure(s) (please identify
below):corresponding PCT/US03/12521
PCT Search Report [3 pp]; 20
References and Return Card.**SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT**

Firm Name

Alcon Research, Ltd.

Signature

Printed name

Teresa J. Schultz

Date

Reg. No.

40,526

CERTIFICATE OF TRANSMISSION/MAILING

I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below:

Signature

Typed or printed name

Barbara McKenzie

Date

18 February 2005

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

10 Rec'd PTO

28 FEB 2005

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Debra FLEENOR et al.

Serial No: 10/510,585

Filed: 8 October 2004

Examiner:

Group Art Unit:

FOR: Agents Which Regulate, Inhibit, Or Modulate The Activity And/Or Expression Of
Connective Tissue Growth Factor (CTGF) As A Unique Means To Both Lower
Intraocular Pressure And Treat Glaucomatous Retinopathies/Optic Neuropathies

**INFORMATION DISCLOSURE STATEMENT
PURSUANT TO 37 C.F.R. 1.56, 1.97, AND 1.98**

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Pursuant to the duty of disclosure under 37 C.F.R. 1.56, 1.97, and 1.98, Applicants submit the patents, articles, and other information referenced in the specification as filed. The references are listed on the attached PTO Form 1449. Applicants are submitting copies of the foreign patents and non-patent literature in accordance with 37 CFR 1.98(a)(2), copies of the U.S. patents are not enclosed.

A copy of the International Search Report issued in the PCT application, of which the present application is a 35 U.S.C. §371 application, is also included for the Examiner's convenience.


Applicants request that the listed patents, articles, and other information be considered during prosecution of this application and that they appear among the "References Cited" on any patent issuing herefrom.

Respectfully submitted,

18 Feb. 2005

Date

By:



Teresa J. Schultz

Registration No. 40,256

817-551-4231

Address for Correspondence:
Alcon Research, Ltd.
Attn: Teresa J. Schultz
6201 S. Freeway, Mail Code Q-148
Fort Worth, TX 76134-2099
Attorney Docket No.: 2354 US F

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Complete if Known

Application Number	10/510,585
Filing Date	8 October 2004
First Named Inventor	Debra FLEENOR et al.
Art Unit	
Examiner Name	
Attorney Docket Number	2354 US F

Sheet 1 of 3

U. S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
		US- PA 2004/005319	01/08/2004	Grotendorst et al.	
		US- 5,408,040	04/18/1995	Grotendorst et al.	
		US- 5,585,270	12/17/1996	Grotendorst et al.	
		US- 6,069,006	05/30/2000	Grotendorst et al.	
		US- 6,150,101	11/21/2000	Grotendorst et al.	
		US- 6,190,884	02/20/2001	Grotendorst et al.	
		US- 6,232,064	05/15/2001	Grotendorst et al.	
		US- 6,348,329	02/19/2002	Schmidt et al.	
		US- 6,358,741	03/19/2002	Schmidt et al.	
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T ⁶
		Country Code ³ "Number" ⁴ "Kind Code" ⁵ (if known)				
		WO 03/027275 A1	04/03/2003	Alcon, Inc.		
		WO 03/092584 A2	11/13/2003	Alcon, Inc.		

Examiner
SignatureDate
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

PTO/SB/08B (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Complete if Known

Application Number	10/510,585
Filing Date	8 October 2004
First Named Inventor	Debra FLEENOR et al.
Art Unit	
Examiner Name	
Attorney Docket Number	2354 US F

Sheet

2

of

3

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	B1	Bain, J., H. McLauchlan, et al., "The specificities of protein kinase inhibitors: an update" BIOCHEM J 371(Pt 1):199-204 (2003)	
	B2	Bengtsson, "Incidence of manifest glaucoma," BR J OPHTHALMOL, vol 73, pp 483-487 (1989)	
	B3	Coghlan, M. P. et al., "Selective small molecule inhibitors of glycogen synthase kinase-3 modulate glycogen metabolism and gene transcription" CHEM BIOL 7(10):793-803 (2000)	
	B4	Cohen, P. and Frame, S., "The renaissance of GSK3" NAT REV MOL CELL BIOL 2(10):769-776 (2001)	
	B5	Davis, S. T. et al., "Prevention of chemotherapy-induced alopecia in rats by CDK inhibitors" SCIENCE 291(5501):134-137 (2001)	
	B6	Hardcastle, I. R. et al., "Designing inhibitors of cyclin-dependent kinases" ANNU REV PHARMACOL TOXICOL 42:325-348 (2002)	
	B7	Knockaert, M. et al., "Pharmacological inhibitors of cyclin-dependent kinases" TRENDS PHARMACOL SCI 23(9):417-425 (2002)	
	B8	Kothapalli, D. and Grotendorst, G.R., "CTGF modulates cell cycle progression in cAMP-arrested NRK fibroblasts" J CELL PHYSIOL 182(1):119-126 (2000)	
	B9	Leost, M. et al., "Paullones are potent inhibitors of glycogen synthase kinase-3beta and cyclin-dependent kinase 5/p25" EUR J BIOCHEM 267(19):5983-5994 (2000)	
	B10	Leske MC, et al., AMERICAN JOURNAL OF EPIDEMIOLOGY, 118(2):166-191 (Aug 1983)	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

10 Nov 2004

28 FEB 2005

PTO/SB/08B (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Complete if Known

Application Number	10/510,585
Filing Date	8 October 2004
First Named Inventor	Debra FLEENOR et al.
Art Unit	
Examiner Name	
Attorney Docket Number	2354 US F

Sheet

3

of

3

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	C1	Park, S. K., Kim, J., Seomun, Y., Choi, J., Kim, D. H., Han, I. O., Lee, E. H., Chung, S. K., Joo, C. K., "Hydrogen Peroxide is a Novel Inducer of Connective Tissue Growth Factor," Biochem. Biophys. Res. Commun. 284(4):966-971 (2001)	
	C2	Schwab, J. M., Postler, E., Nguyen, T. D., Mittelbronn, M., Meyermann, R., Schluesener, H. J., "Connective Tissue Growth Factor is Expressed by a Subset of Reactive Astrocytes in Human Cerebral Infarction," Neuropathology and Applied. Neurobiology 26(5):434-440 (2000)	
	C3	Schwab, J. M., Beschorner, R., Nguyen, T. D., Meyermann, R., Schluesener, H. J., "Differential Cellular Accumulation of Connective Tissue Growth Factor Defines a Subset of Reactive Astrocytes, Invading Fibroblasts, and Endothelial Cells Following Central Nervous System Injury in	
	C4	Shepard et al., "Delayed Secondary Glucocorticoid Responsiveness of MYOC in Human Trabecular Meshwork Cells", IOVS 42:3173-3181 (2001)	
	C5	Strong, N. P., "How optometrists screen for glaucoma: A survey", Ophthal. Physiol. Opt., 12:3-7 (1992)	
	C6	Vaughan, D. et al., In: GENERAL OPHTHALMOLOGY, Appleton & Lange, Norwalk, Conn., pp. 213-230 (1992)	
	C7	Wang et al., "Optimal procedure for extracting RNA from human ocular tissues and expression profiling of the congenital glaucoma gene FOXC1 using quantitative RT-PCR", Mol. Vis. 7:89-94 (2001)	
	C8	Willson, T. M. et al., "The PPARs: from orphan receptors to drug discovery" J MED CHEM 43(4):527-550 (2000)	
	C9	Woodgett, J. R., "Judging a protein by more than its name: GSK-3" SCIENCE'S STKE 2001(100):1-11 (2001)	
	C10	Zaharevitz, D. W. et al., "Discovery and initial characterization of the paullones, a novel class of small-molecule inhibitors of cyclin-dependent kinases" CANCER RES 59(11):2566-2569 (1999)	

Examiner
SignatureDate
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.